Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 9 October 2017

Xbrane Biopharma AB appoints Dina Jurman, Head of Clinical Affairs, to management team

Xbrane Biopharma AB    

Published: 20:30 CEST 09-10-2017 /GlobeNewswire /Source: Xbrane Biopharma AB / : XBRANE /ISIN: SE0007789409

Xbrane Biopharma AB appoints Dina Jurman, Head of Clinical Affairs, to management team

Press release




Xbrane Biopharma AB (publ) has appointed Dina Jurman, Head of Clinical Affairs at Xbrane, to its management team. Dina holds a M.Sc. in Biomedicine from Uppsala University and has previously worked as Director Clinical Operations at IRW Consulting AB as well as Clinical Operations Manager consultant at Amgen Sweden. Dina started at Xbrane on 4 September, 2017 and is since 9 October, 2017 a part of Xbrane's management team.



About Xbrane

Xbrane is a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables. Xbrane has world leading expertise in developing generics for long acting injectable drugs and proprietary high-yield protein expression technology for the development of biosimilars. Xbrane's headquarter is located in Solna outside of Stockholm and the company's in-house research and development facilities are located in Sweden and Italy. Xbrane is listed at Nasdaq First North since February 3rd, 2016 under the name Xbrane and Avanza Bank AB is Xbrane's certified adviser. For more information see www.xbrane.com.


For further information, please contact:

Martin Åmark


M: +46 (0) 763-093 777

E: martin.amark@xbrane.com


Susanna Helgesen

CFO/IR, Xbrane Biopharma AB

M: +46 (0) 708-278 636

E: susanna.helgesen@xbrane.com


This information is information that Xbrane Biopharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 20:30 October 9, 2017.


Xbrane appoints Dina Jurman to management team

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of Nasdaq Corporate Solutions clients. Source: Xbrane Biopharma AB, Stureplan 15, Stockholm 111 45, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.